Starting prior to founding Medical Minds, and spanning more than 20 years of product evolution, our team has contributed to healthcare professional and consumer promotion/education―prelaunch, launch and beyond―in both medical and aesthetic dermatology.
Team Experience: Comprehensive Education and Promotion in the Prelaunch/Launch of Medical and Aesthetic Dermatology Products
|Aesthetics||Obaji/NuDerm®; Neutrogena/pipeline products|
|Psoriasis/psoriatic arthritis||Galderma/Clobex®; Genentech/Raptiva®; Lilly/Talz®|
|Tinea pedis||Novan/topical nitric oxide|
Psoriasis and Psoriatic Arthritis
Clobex®(clobetasol proprionate): Prior to the introduction of biologic therapy, the standard treatment for psoriasis was topical and UV therapy. Our work in psoriasis began with educational programs related to topical therapy for moderate to severe psoriasis with different formulations of Clobex®(clobetasol proprionate).
PsoriasisTx.com: When biologic therapies were introduced, systemic therapy was a new treatment category in dermatology. Our team created PsoriasisTx.com, a highly successful disease education website that supported the adoption of biologic therapy. Regular contributions from leading physician and nurse opinion leaders covered guidelines and data on new approaches to therapy. In its third year, the monthly average of unique visitors was 4,442 out of a total audience of approximately 15,000 prescribers.
Raptiva®(efalizumab): Our team supported Genentech over a 5-year period planning and executing a prelaunch/launch educational program for Raptiva®(efalizumab), one of the first biologic therapies in psoriasis.
Talz®(ixekizumab): Subsequently, Eli Lilly engaged us to develop an educational program focused on IL-17 inhibitors in psoriasis related to prelaunch education for Talz®(ixekizumab). Building on our long-term relationships with the dermatology community we recruited opinion leaders and managed an international advisory board that supported prelaunch activities.